Evidence map›Paper›PMID 42315637›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia study.

Claudia Leslie, Zeyad Al-Ogaili, Leone Oh, Tim Slattery, Sachin Shaji, Gabriela Marsavela, Alana Mills, Caroline Stone, Tom Ferguson

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Claudia LeslieDepartment of Medical Oncology, Fiona Stanley Hospital, Murdoch, Australia, Western Australia. Claudia.leslie@health.wa.gov.au.ORCID 0009-0003-0981-7017
Zeyad Al-OgailiDepartment of Nuclear Medicine, Fiona Stanley Hospital, Western Australia, Murdoch, Australia.
Leone OhDepartment of Medical Oncology, Fiona Stanley Hospital, Murdoch, Australia, Western Australia.
Tim SlatteryDepartment of Medical Oncology, Fiona Stanley Hospital, Murdoch, Australia, Western Australia.
Sachin ShajiDepartment of Medical Oncology, Fiona Stanley Hospital, Murdoch, Australia, Western Australia.
Gabriela MarsavelaDepartment of Medical Oncology, Fiona Stanley Hospital, Murdoch, Australia, Western Australia.
Alana MillsDepartment of Medical Oncology, Fiona Stanley Hospital, Murdoch, Australia, Western Australia.
Caroline StoneDepartment of Medical Oncology, Fiona Stanley Hospital, Murdoch, Australia, Western Australia.
Tom FergusonDepartment of Medical Oncology, Fiona Stanley Hospital, Murdoch, Australia, Western Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLu-PSMA is an effective therapy for mCRPC. Capecitabine is an established radiosensitiser in several solid tumours and may enhance therapeutic response when combined with radioligand therapy. We evaluated the safety and maximum tolerated dose (MTD) of capecitabine with Lu-PSMA in a heavily pre-treated mCRPC cohort.

methodsMen with mCRPC previously treated with ≥ 1 taxane and ≥ 1 androgen receptor pathway inhibitor, and deemed suitable for Lu-PSMA on PSMA-PET, were enrolled in a 3 + 3 dose-escalation study. Capecitabine was administered at four dose levels (275 mg/m

results12 patients received at least one dose of Lu-PSMA. Median age was 75. No dose-limiting toxicities occurred, establishing the MTD at 1000 mg/m

conclusionCapecitabine 1000 mg/m

Indexed as

CapecitabineDipeptidesGlutamate Carboxypeptidase IILutetiumProstatic Neoplasms, Castration-ResistantRadiation-Sensitizing AgentsRadioisotopesAgedAged, 80 and overAntigens, SurfaceHumansMaleMaximum Tolerated DoseMiddle AgedNeoplasm MetastasisProstate-Specific AntigenAntigens, SurfaceCapecitabineDipeptidesGlutamate Carboxypeptidase IILutetiumLutetium-177lutetium (177Lu) vipivotide tetraxetanProstate-Specific AntigenRadiation-Sensitizing AgentsRadioisotopesCapecitabineLutetium-177Prostate cancerPSMA-targeted therapyRadioligand therapy

Identifiers

PMID42315637
PMCPMC13526046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.